Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Prevalence of Huntington's disease
11 evidence topics · 15 sources
Diagnosed prevalence by Shoulson-Fahn stage: share in stages 1 and 2
“The model estimates that in 2020, there were 66,787 individuals diagnosed with HD in the 8 included countries, of whom 62-63% were in Shoulson-Fahn stages 1 and 2 (with less severely limited functional capacity than those in stages 3-5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Data on staging distribution at diagnosis, progression, and mortality were derived from Enroll-HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor statement: people with Huntington's disease in the United States, European Union, and United Kingdom
Sponsor estimate of the U.S. population treatable at launch
| U.S. population segment | Sponsor estimate |
|---|---|
| Initial treatable patients at launch (management estimate) | “~6,000” |
| Diagnosed HD | “~20,000 patients” |
| Symptomatic HD | “~40,000 patients” |
| Genetically identifiable HD | “~100,000 patients” |
Sponsor risk disclosure: addressable population may be smaller than projected
Global prevalence: updated systematic review and meta-analysis
Global prevalence: systematic review and meta-analysis, by region
“The worldwide service-based prevalence of HD, based on a meta-analysis (n = 13 studies), was 2.71 per 100,000 (95% CI: 1.55-4.72). Eleven studies were conducted in Europe, North American, and Australia, with an overall prevalence of 5.70 per 100,000 (95% CI: 4.42-7.35). Three studies were conducted in Asia, with an overall prevalence of 0.40 per 100,000 (95% CI: 0.26-0.61).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Geographic variation and prevalence trends
“The prevalence of HD varies more than tenfold between different geographical regions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was evidence of an increasing prevalence of between 15 and 20% per decade in studies from Australia, North America and Western Europe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: symptomatic and at-risk population
United States: claims-based prevalence
“In the Medicare population, 1,941 prevalent and 819 incident cases of HD were identified in 2017, corresponding to a prevalence proportion of 13.1 per 100,000 persons and incidence rate of 6.1 per 100,000 person-years. In the Medicaid population, 353 prevalent cases of HD were identified in 2014, corresponding to a prevalence proportion of 15.2 per 100,000 persons.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United Kingdom: primary care prevalence
“The estimated prevalence (expressed per 100 000 population) rose from 5.4 (95% CI 3.8 to 7.5) in 1990 to 12.3 (95% CI 11.2 to 13.5) in 2010.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Annual prevalence steadily increased throughout the study period, with prevalence estimates ranging from 4.3 cases (3.6–5.1) per 100,000 in 2000 to 9.2 cases (8.1–10.5) per 100,000 people in 2018 (β = 0.27, p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote